Position in IFRX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$7,448,000
New position
Shares Held
3,325,000
first reported quarter
Ownership
2.26%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#7
of 62 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026FARALLON CAPITAL MANAGEMENT LLC holds $7,398,148,665 across 26 Biotechnology names. IFRX ranks #21 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
13,670,881 | $2,537,793,074 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
10,743,063 | $800,143,332 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
6,348,906 | $778,248,897 | |
| 4 | EXEL |
Exelixis, Inc.
|
13,468,010 | $732,794,424 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
14,309,000 | $506,395,510 | |
| 6 | TNGX |
Tango Therapeutics, Inc.
|
12,277,000 | $383,779,020 | |
| 7 | BEAM |
Beam Therapeutics Inc.
|
10,236,396 | $351,313,110 | |
| 8 | 8,989,098 | $336,372,047 |
All Filings in IFRX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,448,000 | 3,325,000 | Shares | Other | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||